Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia

International Journal of Cardiology

Volumn 167, Issue 1, 2013, Pages 225-231

  Chen, Fabian ^a   Maccubbin, Darbie ^a   Yan, Lizhen ^a   Sirah, Waheeda ^a   Chen, Erluo ^a   Sisk, Christine McCrary ^a   Davidson, Michael ^b   Blomqvist, Peder ^c   McKenney, James M ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b RADIANT RESEARCH   (United States)

^c Läkarhuset   (Sweden)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Laropiprant; Lipoproteins; Mixed hyperlipidemia; Niacin; Statin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT PLUS NICOTINIC ACID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUSHING; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MIXED HYPERLIPIDEMIA; MULTICENTER STUDY; MYALGIA; MYOPATHY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SIDE EFFECT; TOXIC HEPATITIS;

ADULT; AGED; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; INDOLES; LIPIDS; MALE; MIDDLE AGED; NIACIN; PYRROLES; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84878602155     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.12.103     Document Type: Article

References (18)

1. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report Circulation 106 2002 3143 3421
2. B.G. Brown, L. Hillger, X.Q. Zhao, D. Poulin, and J.J. Albers Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS trial. Familial atherosclerosis treatment study Ann N Y Acad Sci 748 1995 407 417
3. B.G. Brown, X.Q. Zhao, and A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
4. P.L. Canner, K.G. Berge, and N.K. Wenger Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
5. The coronary drug project research group. The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine JAMA 220 1972 996 1008
6. The coronary drug project research group Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
7. K. Cheng, T.J. Wu, and K.K. Wu Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans Proc Natl Acad Sci U S A 103 2006 6682 6687
8. C.F. Sturino, G. O'Neill, and N. Lachance Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7- fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocy clopenta[b]indol-3-yl]-acetic acid (MK-0524) J Med Chem 50 2007 794 806
9. D. Maccubbin, W. Sirah, A. Betteridge, Q. Yu, C. McCrary Sisk, and H. Bays Lipid-altering efficacy and tolerability profile of extended release niacin/laropiprant in patients with primary hypercholesterolemia or mixed hyperlipidemia Eur Heart J 28 108 2007
10. J.F. Paolini, Y.B. Mitchel, and R. Reyes Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia Am J Cardiol 101 2008 625 630
11. G. Gleim, C.M. Ballantyne, and N. Liu Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia Br J Cardiol 16 2009 90 97
12. J.R. Guyton Extended-release niacin for modifying the lipoprotein profile Expert Opin Pharmacother 5 2004 1385 1398
13. J. Danesh, R. Collins, and R. Peto Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies Circulation 102 2000 1082 1085
14. J.R. Guyton, and H.E. Bays Safety considerations with niacin therapy Am J Cardiol 99 2007 22C 31C
15. J.I. Rader, R.J. Calvert, and J.N. Hathcock Hepatic toxicity of unmodified and time-release preparations of niacin Am J Med 92 1992 77 81
16. F. Tato, G.L. Vega, and S.M. Grundy Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase Am J Cardiol 81 1998 805 807
17. M.B. Elam, D.B. Hunninghake, and K.B. Davis Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial JAMA 284 2000 1263 1270
18. S.M. Grundy, G.L. Vega, and M.E. McGovern Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial Arch Intern Med 162 2002 1568 1576